The St. Louis - Cape Girardeau CCOP is a consortium of six hospitals in two separate bi-state health service areas in Eastern Missouri and Western Illinois. The investigators from the St. Louis Metropolitan area are affiliated with one or more of the five hospitals in the consortium and have worked together for the past 10 years in cancer treatment research protocols and more recently, in cancer control research studies. The Cape Girardeau investigators have worked with the CCOP for the past four years and are affiliated with the two hospitals in that city. During the next five years, we expect to accrue at least 80 credits per year for cancer treatment research protocols of the NSABP and SWOG and at least 100 credits (new participants and followup) per year for cancer control and prevention studies. These cancer control credits will be derived primarily from our participation in the Breast Cancer Prevention Trial and the Prostate Cancer Prevention Trial. We will continue to provide high quality data to the Southwest Oncology Group and the National Surgical Adjuvant Breast Program which are our research bases, utilizing the data management system developed during the past six years. In summary, we will continue our excellent performance of the past 10 years in the cancer treatment research arena and utilize our expertise in cancer control research studies as well. The past experience and abilities of the investigators and data managers provides a strong base for continuing development of this Community Clinical Oncology Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035128-12
Application #
2088848
Study Section
Special Emphasis Panel (SRC (74))
Project Start
1987-06-01
Project End
1999-05-31
Budget Start
1995-06-01
Budget End
1996-05-31
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
St. John's Mercy Medical Center
Department
Type
DUNS #
071958003
City
Saint Louis
State
MO
Country
United States
Zip Code
63141
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Yao, James C; Guthrie, Katherine A; Moran, Cesar et al. (2017) Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol 35:1695-1703
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7

Showing the most recent 10 out of 108 publications